MODTX.ST Stock Analysis
MO
Uncovered
Modus Therapeutics Holding AB is uncovered by Eyestock quantitative analysis.
Modus Therapeutics Holding AB operates as a biotechnology company. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2021-07-22. The firm's focus in the short term is to develop sevuparin for patients with sepsis / septic shock, a serious and often fatal condition. Sevuparin is a state-of-the-art patented polysaccharide drug with a multimodal mechanism of action, including anti-inflammatory, anti-adhesive and anti-aggregated effects. Sevuparin is a heparinoid with markedly weakened anticoagulant function that allows significantly higher doses to be given compared to regular heparinoids, without the risk of bleeding side effects.